公开(公告)号：US20240285635A1

公开(公告)日：2024-08-29

申请号：US18569182

申请日：2022-06-21

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  SHOUYAO HOLDINGS (BEIJING) CO., LTD. ,  LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.

发明人： LIFAN TU ,  XIQUAN ZHANG ,  XUNQIANG WANG ,  DING YU ,  JIANQIANG HUANG

IPC分类号： A61K31/519 ,  A61P37/06

CPC分类号： A61K31/519 ,  A61P37/06

摘要： The present invention relates to the use of a pyrrolopyrimidine compound and a pharmaceutical composition thereof for treating chronic graft versus host disease, and particularly relates to the use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating chronic graft versus host disease.

公开(公告)号：US20240270857A1

公开(公告)日：2024-08-15

申请号：US18569115

申请日：2022-06-17

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Xi LONG ,  Hongjiang XU ,  Wei SHI ,  Liangliang WANG ,  Zhenzhen LU

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P37/06

CPC分类号： C07K16/2866 ,  A61P37/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

摘要： An anti-IL-36R antibody and a use thereof, in particular, a mouse, chimeric or humanized antibody or an antigen-binding fragment thereof binding to IL-36R; a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, as well as an expression vector and host cell used to express the antibody or the antigen-binding fragment thereof. In addition, a preparation method and a use of the antibody or the antigen-binding fragment thereof, including treatment and prevention of IL-36/IL-36R-mediated diseases and disorders.

公开(公告)号：US12054482B2

公开(公告)日：2024-08-06

申请号：US17276920

申请日：2019-09-19

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Zhe Cai ,  Fei Sun ,  Charles Z. Ding ,  Shuhui Chen

IPC分类号： C07D471/04 ,  A61K31/549 ,  A61P37/02

CPC分类号： C07D471/04 ,  A61K31/549 ,  A61P37/02

摘要： A TLR8 (Toll-like receptor 8) agonist, a compound of the structure shown in formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240101551A1

公开(公告)日：2024-03-28

申请号：US17793588

申请日：2021-01-19

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  SHOUYAO HOLDINGS (BEIJING) CO., LTD.

发明人： Wenwei XU ,  Zhenliang SHAN ,  Yingya ZHANG ,  Guoliang ZHANG ,  Yun GE ,  Aiming ZHANG ,  Xiquan ZHANG

IPC分类号： C07D471/04 ,  A61P35/02

CPC分类号： C07D471/04 ,  A61P35/02 ,  C07B2200/13

摘要： A crystal form and salt form of a bromine domain protein inhibitor represented by formula (I), a preparation method therefor, and a use of the crystal form and salt form in the preparation of a drug for treating diseases mediated by BET protein.

公开(公告)号：US11931506B2

公开(公告)日：2024-03-19

申请号：US16766646

申请日：2018-11-22

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： Changhui Li ,  Ping Dong ,  Xuebing Zhu

IPC分类号： A61M15/00

CPC分类号： A61M15/0035 ,  A61M15/0008 ,  A61M15/0051

摘要： A novel dry powder inhaler. By providing a plurality of capsule chambers (1a, 1b, 1c, 1d) arranged in parallel in a capsule dry powder inhalation device, a medicine dispenser containing active components of a composite product or their mixture separately is provided. The dry powder inhaler has a simple structure and is convenient to operate. In addition, the parameters of air inlet channels and an air outlet channel can be adjusted by means of each capsule chamber (1a, 1b, 1c, 1d) according to the properties of powder of a medicine or a combination, so as to provide an appropriate particle distribution for each active component.

公开(公告)号：US11891405B2

公开(公告)日：2024-02-06

申请号：US17276025

申请日：2019-09-12

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Yinsheng Zhang ,  Hongjiang Xu ,  Jing Ren ,  Qinglin Wang ,  Zheyang Wu ,  Chao Jin ,  Wei Shi ,  Xiaojin Wang ,  Xiangyi He ,  Xiayun Chang ,  Jie Wang ,  Tianxiao Zhao

IPC分类号： C07D519/00

CPC分类号： C07D519/00

摘要： The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.

公开(公告)号：US11866433B2

公开(公告)日：2024-01-09

申请号：US17503141

申请日：2021-10-15

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Chunli Shen ,  Chengde Wu ,  Shenglin Chen ,  Shuhui Chen ,  Xiquan Zhang ,  Xin Tian

IPC分类号： C07D471/04 ,  C07D401/14 ,  C07D403/10 ,  C07D405/14 ,  C07D413/10

CPC分类号： C07D471/04 ,  C07D401/14 ,  C07D403/10 ,  C07D405/14 ,  C07D413/10

摘要： The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

公开(公告)号：US20230404976A1

公开(公告)日：2023-12-21

申请号：US18033897

申请日：2021-11-05

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Zhongnan XU ,  Dandan HUO ,  Hong ZHANG ,  Yanan YU ,  Jianhua XIA ,  Haiying HE

IPC分类号： A61K31/407 ,  A61K31/522 ,  A61K31/683 ,  A61P31/20

CPC分类号： A61K31/407 ,  A61K31/522 ,  A61K31/683 ,  A61P31/20

摘要： A pharmaceutical combination containing a capsid protein inhibitor and a nucleoside analog, selected from entecavir or a pharmaceutically acceptable salt thereof or a solvate thereof, or tenofovir or a pharmaceutically acceptable salt or pharmaceutically acceptable prodrug thereof, as well as a use of said pharmaceutical combination in treating a hepatitis B virus infection. The pharmaceutical combination has a good hepatitis B virus infection-fighting effect.

公开(公告)号：US20230303557A1

公开(公告)日：2023-09-28

申请号：US17931456

申请日：2021-03-18

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Zhe CAI ,  Fei SUN ,  Charles Z. Ding ,  Shuhui CHEN

IPC分类号： C07D471/04

CPC分类号： C07D471/04 ,  C07B2200/13

摘要： Disclosed are a crystalline form of a Toll-like receptor 8 (TLR8) agonist as represented by formula (I) and a preparation method therefor. Further provided is an application of the crystalline form in the preparation of a drug for treating a disease responsive to the TLR8 agonist.

公开(公告)号：US20230263795A1

公开(公告)日：2023-08-24

申请号：US17999028

申请日：2021-06-01

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL

发明人： Xiquan ZHANG ,  Xunqiang Wang ,  Ding Yu ,  Tao LIU ,  Xiaole ZHAN ,  Naiying WU

IPC分类号： A61K31/47 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K31/47 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/545

摘要： Provided are a combined pharmaceutical composition of an anti-PD-L1 antibody and a c-Met kinase inhibitor, specifically, a combined pharmaceutical composition of an anti-PD-L1 antibody and N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and the use of the combined pharmaceutical composition in the treatment of cancers, in particular, gastric cancer or liver cancer.